Health2 sources

FDA Approves Cemdisiran for Generalized Myasthenia Gravis

  • The FDA approved cemdisiran (Livsayis) for treating generalized myasthenia gravis in adults.
  • Cemdisiran is a subcutaneous small interfering RNA (siRNA) therapy.
  • The drug is specifically for adults who are anti-acetylcholine receptor (AChR) antibody-positive.
  • Regeneron announced the approval of cemdisiran for this condition.
  • The approval was reported by both MedPage Today and Reuters.